AnalytiCon Discovery GmbH

Potsdam, Germany

AnalytiCon Discovery GmbH

Potsdam, Germany
SEARCH FILTERS
Time filter
Source Type

Patent
AnalytiCon Discovery GmbH | Date: 2017-01-04

Suggested are compositions comprising natural stilbenes as a sweetener or sweetener enhancer in preparations and compositions, especially oral edible compositions comprising them.


Patent
AnalytiCon Discovery GmbH | Date: 2013-12-05

Suggested are triterpene-glycoside compounds, which are obtainable by the extraction of Momordica grosvenorii (Siraitia grosvenori) which are useful as a sweetener or sweetener enhancer in preparations and compositions, especially oral edible compositions.


Weidner C.,Max Planck Institute for Molecular Genetics | Weidner C.,Free University of Berlin | De Groot J.C.,Helmholtz Center for Infection Research | Prasad A.,Cornell University | And 17 more authors.
Proceedings of the National Academy of Sciences of the United States of America | Year: 2012

Given worldwide increases in the incidence of obesity and type 2 diabetes, new strategies for preventing and treating metabolic diseases are needed. The nuclear receptor PPARγ (peroxisome proliferator- activated receptor gamma) plays a central role in lipid and glucose metabolism; however, current PPARγ-targeting drugs are characterized by undesirable side effects. Natural products from edible biomaterial provide a structurally diverse resource to alleviate complex disorders via tailored nutritional intervention. We identified a family of natural products, the amorfrutins, from edible parts of two legumes, Glycyrrhiza foetida and Amorpha fruticosa, as structurally new and powerful antidiabetics with unprecedented effects for a dietary molecule. Amorfrutins bind to and activate PPARγ, which results in selective gene expression and physiological profiles markedly different fromactivation by current synthetic PPARγ drugs. In diet-induced obese and db/db mice, amorfrutin treatment strongly improves insulin resistance and other metabolic and inflammatory parameters without concomitant increase of fat storage or other unwanted side effects such as hepatoxicity. These results show that selective PPARγ-activation by diet-derived ligands may constitute a promising approach to combat metabolic disease.


Healthspan (the life period when one is generally healthy and free from serious disease) depends on nature (genetic make-up) and nurture (environmental influences, from the earliest stages of development throughout life). Genetic studies increasingly reveal mutations and polymorphisms that may affect healthspan. Similarly, claims abound about lifestyle modifications or treatments improving healthspan. In both cases, rigorous testing is hampered by the long lifespan of model organisms like mice (let alone humans) and the difficulty of introducing genetic changes to examine the phenotype of the altered genome. We will develop C. elegans as a healthspan model. Already validated extensively as an ageing model, this organism can be readily modified genetically, and effects of environmental manipulations on healthspan can be measured in days or weeks. Once validated as a healthspan model, it can be used for an initial assessment of preventive and therapeutic measures for humans, as well as for risk identification and the initial evaluation of potential biomarkers. It will also prove useful to study interactions between genetic and various environmental factors.


Bottger S.,Free University of Berlin | Westhof E.,Free University of Berlin | Siems K.,AnalytiCon Discovery GmbH | Melzig M.F.,Free University of Berlin
Toxicon | Year: 2013

Saponins are amphiphilic secondary plant compounds able to interfere with surfaces and permeabilize membranes. In addition to antimicrobial and anti-inflammatory features, anti-neoplastic activities are described which base on various mechanisms. A very promising anti-cancer strategy is the synergistic enhancement of the cytotoxicity of ribosome-inactivating proteins type I (RIP-I) by suitable saponins. The cytotoxicity of the naturally low cytotoxic activity showing RIP-I can be augmented up to 100,000-fold, if they are applied in combination with appropriate saponins. These saponins have to hold certain structural features.We analyzed 56 different saponins for their non-synergistic, as well as their synergistic cytotoxicity with the RIP-I saporin from Saponaria officinalis L. (Caryophyllaceae). The saponins were assorted into categories, according to their structural features and their cytotoxic behavior, to build up structure-activity relationships. A non-synergistic cytotoxicity as low as possible and a synergistic cytotoxicity as high as possible were desired.The investigations suggest that ideal saponins consist of an oleanane-type scaffold, preferably gypsogenin or quillaic acid, three branched sugars at the C-3-OH-group including glucuronic acid, galactose, xylose and four branched sugars at the C-28-OH-group, including deoxy-sugars and acetyl-residues. © 2013 Elsevier Ltd.


Grant
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-ITN-2008 | Award Amount: 3.73M | Year: 2009

Debilitating degenerative diseases such as non-healing wounds and neurodegeneration do not yet have a cure. They represent a huge unmet medical need worldwide, especially in the aging European population. To reduce the incidence and improve recovery from such ephitelial diseases there is an major need to understand molecular signaling in order to promote stem cell behavior and enhance regeneration and healing. The key objectives of the HEALING network are 1) to train researchers in the fields of molecular signaling, developmental genetics, stem cell biology and small molecule chemistry; 2) to elucidate the mechanisms regulating one of the most promising pathways, Hedgehog-Gli (Hh-Gli) signaling; 3) to manipulate it by the development of specific small molecule agonists for future therapeutic use. Specifically, our research will (a) analyze the basic molecular mechanisms of Hh-Gli signaling in two model organisms and in human cells using leading technologies. In particular, (b) address the mechanisms that ensure controlled Hh-Gli function during skin wound healing and brain repair. (c) develop new small molecule Hh-Gli agonists for use as tools to be used as future therapeutics to enhance wound healing, regeneration and repair in a controlled manner. This network consists of 7 leading academic and research institutions, and 2 biotech companies from 8 European countries. It strengthens existing scientific collaboration, provides complementary expertise and brings together a critical mass for training and research. Additionally, it includes experts from Europe, Canada and Singapore, notably a pioneer in Hh-Gli signaling. HEALING will greatly enhance the training of the next generation of leading scientists in Hh-Gli signaling, stem cells and regenerative medicine. Thus, it will increase the competitiveness of highly skilled staff and of the European biotech industry, which has just recently discovered the role of Hh-Gli signaling in human disease and lags behind the US


Patent
AnalytiCon Discovery GmbH and Sloan Kettering Institute For Cancer Research | Date: 2010-12-01

In one aspect, the instant invention provides novel compounds and pharmaceutical compositions useful for treating proliferative diseases such as cancer. In another aspect, the invention provides methods of using certain compounds in the treatment of proliferative diseases such as cancer. In particular, the instant invention provides methods of treating ocular cancer (e.g., retinoblastoma) using intraarterial infusion to administer inventive compounds locally to the eye of a subject with an ocular cancer.


Patent
AnalytiCon Discovery GmbH | Date: 2014-02-26

Surprisingly, it was found that the administration of plant extracts is efficacious in the blockade of TRPV1 channels. In particular, plant extracts of Mangifera indica and/or Fumaria officinalis and/or Rumex japonicus are efficacious as skin irritation-reducing agent and as an antagonistic agent for TRPV1.


Patent
AnalytiCon Discovery GmbH | Date: 2013-09-06

The present invention relates to an anti-dandruff composition comprising 1-acetoxychavicol acetate (I). Furthermore, the present invention relates to a method for preparing said anti-dandruff composition and the use of said anti-dandruff composition for treating or preventing Malassezia induced dandruff formation. Moreover, the present invention relates to a method for preparing an Alpinia galanga extract and an extract obtainable or obtained by said method as well as the use of this extract for treating Malassezia induced dandruff formation comprising applying an anti-dandruff composition comprising said extract.

Loading AnalytiCon Discovery GmbH collaborators
Loading AnalytiCon Discovery GmbH collaborators